Device type · PLP
High Intensity Ultrasound System For Prostate Tissue Ablation
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
PLP
Gastroenterology & Urology
Device class
Class II
FDA decisions since 2015
13
510(k), De Novo and PMA
Adverse event reports
5
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- High Intensity Ultrasound System For Prostate Tissue Ablation
- Product code
- PLP
- Device class
- Class II
- Review panel
- Gastroenterology & Urology
- Regulation
- 21 CFR 876.4340
- Specialty
- GI, Urology & Nephrology, Urology
- FDA record
- Classification database entry for PLP
Latest FDA decisions
The 8 newest of 13 since 2015.
- Focal One®510(k)
K251910 · Decided Nov 19, 2025 · 152 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
K240296 · Decided May 9, 2024 · 98 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
K231378 · Decided Oct 30, 2023 · 171 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
10 more FDA decisions with a free account
Reports received
5
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
5
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 1 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 2 | 0 | 0 |
| Apr 24 | 0 | 4 | 0 | 0 |
| May 24 | 0 | 1 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 2 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 1 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 1 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 1 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 1 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 1 | 0 | 0 |
| Jul 26 | 0 | 2 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Adverse Event Without Identified Device or Use Problem4
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Fistula4
- Cancer1
- Erectile Dysfunction1
3 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0049-2018 · Started Aug 14, 2017
Reason given: The US FDA has requested the optional energy treatment settings, "medium" and "low" (Software Protocols 02-Medium and 03-Low) be removed from all Ablatherm Integrated Imagining devices in the U.S. until supporting clinical data can be submitted and evaluated by FDA.
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.